Anti-CD25 ADC Combination Therapy for Mixed Tumor Populations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using antibody drug conjugates (ADCs) face challenges in effectively targeting and treating cancers with mixed populations of CD25+ and CD25- cells, as existing therapies often result in toxicity to normal cells and limited efficacy in certain cancer types.
Innovation Solution
Combining an anti-CD25 ADC with secondary agents such as Bruton's Tyrosine Kinase inhibitors, PD1 antagonists, PD-L1 antagonists, GITR agonists, OX40 agonists, CTLA-4 antagonists, Fludarabine, or Cytarabine to enhance targeted delivery and immune response, allowing for the treatment of proliferative diseases like lymphomas and leukemias with both CD25+ and CD25- cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If systemic administration of unconjugated cytotoxic drugs is used to treat cancer, then the drugs can reach all tumor cells, but unacceptable levels of toxicity to normal cells occur
Solution Approach 1:
The treatment approach is segmented into two distinct components: a targeting antibody that specifically binds to CD25 antigen on tumor cells, and a cytotoxic drug payload. This segmentation allows the drug to be delivered selectively only to cells expressing the target antigen, avoiding systemic exposure of normal cells while maintaining effective concentration at the tumor site.
Solution Approach 2:
The antibody serves as an intermediary molecule that bridges the cytotoxic drug and the target tumor cells. By conjugating the drug to the antibody, the system enables selective delivery through the antibody's specific binding to CD25, acting as a mediator that directs the harmful drug exclusively to malignant cells while sparing normal tissue.
2Manufacturing precision
If anti-CD25 ADC is used to target CD25+ tumor cells, then targeted delivery is achieved, but limited efficacy occurs in cancers with mixed CD25+ and CD25- cell populations
Solution Approach 1:
The invention merges two therapeutic modalities into a single combination treatment: anti-CD25 ADC therapy for targeted killing of CD25+ cells, and secondary agent therapy for broader activity against both CD25+ and CD25- cells. This merging allows simultaneous engagement of multiple cell populations while maintaining selective toxicity through the ADC component.
Solution Approach 2:
The combination therapy establishes continuous anti-tumor activity by addressing both CD25+ cells (via ADC) and CD25- cells (via secondary agents). This continuous action prevents treatment gaps that would occur with single-agent therapy, ensuring all tumor cell subpopulations are targeted throughout the treatment course.
3Productivity
If higher doses of ADC are administered to improve treatment efficacy, then tumor cell killing increases, but toxicity to normal cells increases
Solution Approach 1:
The ADC exhibits local quality by concentrating the cytotoxic effect exclusively at the site of CD25+ tumor cells through specific antibody-antigen binding. This localized action allows high drug concentration at the target site without proportionally increasing systemic toxicity, as the drug remains bound to the antibody and is delivered only where the target antigen is present.
Data Source
AI summary
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.